InDex Pharmaceuticals AB

📍 Solna, Sweden🗓 Founded 2000👥 23 employees💰 Last funded Apr 2020
Pharmaceutical Manufacturing🌐 indexpharma.com
Website LinkedIn
InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
2
Total investors
0
Early stage
1
Mid stage
0
Late stage
2000
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
2
Frequently asked questions
Who invested in InDex Pharmaceuticals AB?
InDex Pharmaceuticals AB has 2 investors on record on gritt.io, 1 mid-stage.
When did InDex Pharmaceuticals AB last raise funding?
The most recent investment in InDex Pharmaceuticals AB recorded on gritt.io was in April 2020.
When was InDex Pharmaceuticals AB founded?
InDex Pharmaceuticals AB was founded in 2000.
What industry is InDex Pharmaceuticals AB in?
InDex Pharmaceuticals AB operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is InDex Pharmaceuticals AB based?
InDex Pharmaceuticals AB is headquartered in Solna, Sweden.